View ValuationJune Industries 将来の成長Future 基準チェック /06現在、 June Industriesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率IT 収益成長8.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 24June Industries Limited to Report Q4, 2026 Results on May 15, 2026June Industries Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 15, 2026Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹0.02 loss per share (vs ₹0 in 3Q 2025)Third quarter 2026 results: ₹0.02 loss per share (further deteriorated from ₹0 in 3Q 2025). Net loss: ₹942.0k (loss widened ₹920.0k from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.お知らせ • Jan 21June Industries Limited to Report Q3, 2026 Results on Feb 10, 2026June Industries Limited announced that they will report Q3, 2026 results on Feb 10, 2026New Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹780k revenue, or US$8.6k). Market cap is less than US$10m (₹400.9m market cap, or US$4.44m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).Buy Or Sell Opportunity • Nov 20Now 23% undervaluedOver the last 90 days, the stock has risen 4.8% to ₹10.19. The fair value is estimated to be ₹13.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 133%.Reported Earnings • Nov 18First half 2026 earnings released: ₹0.018 loss per share (vs ₹0.002 profit in 1H 2025)First half 2026 results: ₹0.018 loss per share (down from ₹0.002 profit in 1H 2025). Net loss: ₹869.0k (down ₹947.0k from profit in 1H 2025). Over the last 3 years on average, earnings per share has increased by 133% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.お知らせ • Nov 03Kashyap Tele-Medicines Limited to Report First Half, 2026 Results on Nov 12, 2025Kashyap Tele-Medicines Limited announced that they will report first half, 2026 results on Nov 12, 2025お知らせ • Sep 26+ 1 more updateKashyap Tele-Medicines Limited Appoints Kalpesh Bipin Sheth as Managing Director, Effective May 23, 2025Kashyap Tele-Medicines Limited at its AGM held on September 24, 2025 announced the appointment of Mr. Kalpesh Bipin Sheth (DIN: 00405151) as Managing Director of the Company, effective 23rd May, 2025 for the period of five consecutive years.お知らせ • Aug 25Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025, at 11:30 Indian Standard Time.Reported Earnings • Aug 15First quarter 2026 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in 1Q 2025)First quarter 2026 results: ₹0.006 loss per share (down from ₹0.001 profit in 1Q 2025). Net loss: ₹298.0k (down ₹332.0k from profit in 1Q 2025).お知らせ • Aug 09Kashyap Tele-Medicines Limited to Report Q1, 2026 Results on Aug 14, 2025Kashyap Tele-Medicines Limited announced that they will report Q1, 2026 results on Aug 14, 2025Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Non-Executive & Independent Director Hiren Mehta was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • May 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹860k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹860k free cash flow). Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹432.8m market cap, or US$5.08m).お知らせ • May 15Kashyap Tele-Medicines Limited to Report Q4, 2025 Results on May 23, 2025Kashyap Tele-Medicines Limited announced that they will report Q4, 2025 results on May 23, 2025お知らせ • Apr 07Kashyap Tele-Medicines Limited Announces Resignation of Ms. Jyoti Sahu as Whole Time Company Secretary, Compliance Officer, Effective April 6, 2025Kashyap Tele-Medicines Limited announced resignation of Ms. Jyoti Sahu (ICSI A72072) from the position of Whole Time Company Secretary, Compliance Officer and Key Managerial Personnel and she shall not be associated with the Company with effect from 6th April, 2025 to explore further professional growth opportunities. Further there are no other material reasons for resignation other than the one mentioned in her resignation letter dated 5th April, 2025.Reported Earnings • Feb 13Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹0. Revenue: ₹390.0k (down 14% from 3Q 2024). Net loss: ₹22.0k (down 375% from profit in 3Q 2024).お知らせ • Feb 05Kashyap Tele-Medicines Limited to Report Q3, 2025 Results on Feb 12, 2025Kashyap Tele-Medicines Limited announced that they will report Q3, 2025 results on Feb 12, 2025Reported Earnings • Nov 14Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹0.001. Revenue: ₹550.0k (down 9.8% from 2Q 2024). Net income: ₹44.0k (up ₹42.0k from 2Q 2024). Profit margin: 8.0% (up from 0.3% in 2Q 2024). The increase in margin was driven by lower expenses.New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹110.2m market cap, or US$1.31m).お知らせ • Nov 06Kashyap Tele-Medicines Limited to Report Q2, 2025 Results on Nov 11, 2024Kashyap Tele-Medicines Limited announced that they will report Q2, 2025 results on Nov 11, 2024お知らせ • Aug 28Kashyap Tele-Medicines Limited Announces Cessation of Surabhi Agrawal from the Post of Non-Executive Independent DirectorKashyap Tele-Medicines Limited announced that the Board of Directors in its meeting held on 28 August, 2024, has inter-alia considered and taken note of the cessation of Mrs. Surabhi Agrawal from the post of Non-Executive Independent Director of the Company effective from 22 August, 2024 upon completion of second term of five consecutive years on 21 August, 2024.お知らせ • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2025 Results on Aug 05, 2024Kashyap Tele-Medicines Limited announced that they will report Q1, 2025 results on Aug 05, 2024Reported Earnings • Jul 26Full year 2024 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in FY 2023)Full year 2024 results: ₹0.006 loss per share (down from ₹0.001 profit in FY 2023). Revenue: ₹1.92m (down 2.3% from FY 2023). Net loss: ₹300.0k (down ₹331.0k from profit in FY 2023).お知らせ • Jul 22Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024, at 15:00 Indian Standard Time.お知らせ • Jul 18Kashyap Tele-Medicines Limited Announces Change in Category of Directorship of Amrita Khetan from Non-Executive Non-Independent Director to Non-Executive Independent DirectorKashyap Tele-Medicines Limited at its board meeting held on July 18, 2024 approved change in category of directorship of Mrs. Amrita Khetan (DIN: 02781781) from existing category of "Non-Executive Non-Independent Director" to "Non-Executive Independent Director" of the Company for the first term of 5 consecutive years w.e.f. 19th July, 2024 to 18th July, 2029. Mrs. Amrita Khetan has completed Master of Arts in Sociology from Techno Global University and Bachelor of Arts from Kanpur Vishwavidyalaya. She has approx. 12 years of rich experience in mentorship in Programme Management. She is working as a Team Lead & Pedagogical mentor in Redbricks Education Foundation and also experienced and expertised in strategic thinking and Business management.New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹112.1m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).お知らせ • May 12Kashyap Tele-Medicines Limited to Report Q4, 2024 Results on May 17, 2024Kashyap Tele-Medicines Limited announced that they will report Q4, 2024 results on May 17, 2024お知らせ • Feb 28Kashyap Tele-Medicines Limited Appoints Jyoti Sahu as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited at its board meeting held on February 27, 2024, has appointed Ms. Jyoti Sahu (ACS-72072), Member of the Institute of Companies Secretaries of India as Company Secretary and Compliance Officer of the Company with effect from February 27, 2024.New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹119.3m market cap, or US$1.44m).Reported Earnings • Feb 11Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ₹455.0k (down 16% from 3Q 2023). Net income: ₹8.0k (up 33% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses.お知らせ • Feb 01Kashyap Tele-Medicines Limited to Report Q3, 2024 Results on Feb 09, 2024Kashyap Tele-Medicines Limited announced that they will report Q3, 2024 results on Feb 09, 2024お知らせ • Dec 28Kashyap Tele-Medicines Limited Announces Resignation of Mr. Paritosh Trivedi as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited informed that the Board of Directors at their meeting held on 27 December, 2023, considered and approved, resignation of Mr. Paritosh Trivedi, Company Secretary & Compliance Officer of the Company. Accordingly, he shall be relieved from his current responsibilities with effect from closing hours of 27th December, 2023. Reason for change: Resignation due to some personal an unavoidable reasons.お知らせ • Oct 26Kashyap Tele-Medicines Limited to Report Q2, 2024 Results on Nov 06, 2023Kashyap Tele-Medicines Limited announced that they will report Q2, 2024 results on Nov 06, 2023New Risk • Aug 04New major risk - Revenue and earnings growthEarnings have declined by 70% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 70% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹92.6m market cap, or US$1.12m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).お知らせ • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2024 Results on Aug 03, 2023Kashyap Tele-Medicines Limited announced that they will report Q1, 2024 results on Aug 03, 2023Reported Earnings • Jul 15Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).お知らせ • Jul 13Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023, at 12:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2023 together with the Report of the Board of Directors and Report of the Statutory Auditors thereon; to appoint a Director in place of Ms. Amrita Khetan who retires by rotation and being eligible, offers herself for re-appointment; to consider and approve appointment of M/s. Ravi Karia & Associates, Chartered Accountants, Ahmedabad, as Statutory Auditors of the Company and to fix their remuneration; and to consider other matters if any.New Risk • Jun 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹94.5m market cap, or US$1.15m).Reported Earnings • Jun 03Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).お知らせ • May 23Kashyap Tele-Medicines Limited to Report Q4, 2023 Results on May 29, 2023Kashyap Tele-Medicines Limited announced that they will report Q4, 2023 results on May 29, 2023Board Change • Mar 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0 (vs ₹0.002 in 3Q 2022)Third quarter 2023 results: EPS: ₹0 (down from ₹0.002 in 3Q 2022). Revenue: ₹542.0k (down 6.6% from 3Q 2022). Net income: ₹6.0k (down 94% from 3Q 2022). Profit margin: 1.1% (down from 17% in 3Q 2022).お知らせ • Feb 03Kashyap Tele-Medicines Limited to Report Q3, 2023 Results on Feb 10, 2023Kashyap Tele-Medicines Limited announced that they will report Q3, 2023 results on Feb 10, 2023Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: ₹0 (vs ₹0.001 in 2Q 2022)Second quarter 2023 results: EPS: ₹0 (down from ₹0.001 in 2Q 2022). Revenue: ₹510.0k (up 7.4% from 2Q 2022). Net income: ₹13.0k (down 71% from 2Q 2022). Profit margin: 2.5% (down from 9.3% in 2Q 2022).お知らせ • Nov 03Kashyap Tele-Medicines Limited to Report Q2, 2023 Results on Nov 09, 2022Kashyap Tele-Medicines Limited announced that they will report Q2, 2023 results on Nov 09, 2022Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、June Industries は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測BSE:531960 - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20250-2N/AN/AN/A9/30/20251-166N/A6/30/202510N/AN/AN/A3/31/202520-1-1N/A12/31/202420N/AN/AN/A9/30/20242000N/A6/30/202420N/AN/AN/A3/31/20242000N/A12/31/202320N/AN/AN/A9/30/20232000N/A6/30/202320N/AN/AN/A3/31/20232011N/A12/31/20222-17N/AN/AN/A9/30/20222-17-1-1N/A6/30/20222-17N/AN/AN/A3/31/20222-17-1-1N/A12/31/202120N/AN/AN/A9/30/20212011N/A6/30/202120N/AN/AN/A3/31/20212000N/A12/31/202020N/AN/AN/A9/30/202020-1-1N/A6/30/202020N/AN/AN/A3/31/20202000N/A12/31/201920N/AN/AN/A9/30/201920N/AN/AN/A6/30/201920N/AN/AN/A3/31/201920N/A0N/A12/31/201820N/AN/AN/A9/30/201820N/AN/AN/A6/30/201820N/AN/AN/A3/31/201820N/A0N/A12/31/201720N/AN/AN/A9/30/201720N/AN/AN/A6/30/201720N/AN/AN/A3/31/201720N/A-1N/A12/31/201610N/AN/AN/A9/30/201610N/AN/AN/A6/30/201610N/AN/AN/A3/31/201610N/A0N/A12/31/201510N/AN/AN/A9/30/201510N/AN/AN/A6/30/201510N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 531960の予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 531960の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 531960の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 531960の収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 531960の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 531960の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YSoftware 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/20 10:44終値2026/05/18 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋June Industries Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 24June Industries Limited to Report Q4, 2026 Results on May 15, 2026June Industries Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 15, 2026
Reported Earnings • Feb 11Third quarter 2026 earnings released: ₹0.02 loss per share (vs ₹0 in 3Q 2025)Third quarter 2026 results: ₹0.02 loss per share (further deteriorated from ₹0 in 3Q 2025). Net loss: ₹942.0k (loss widened ₹920.0k from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth.
お知らせ • Jan 21June Industries Limited to Report Q3, 2026 Results on Feb 10, 2026June Industries Limited announced that they will report Q3, 2026 results on Feb 10, 2026
New Risk • Dec 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m (₹780k revenue, or US$8.6k). Market cap is less than US$10m (₹400.9m market cap, or US$4.44m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change).
Buy Or Sell Opportunity • Nov 20Now 23% undervaluedOver the last 90 days, the stock has risen 4.8% to ₹10.19. The fair value is estimated to be ₹13.22, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last 3 years. Earnings per share has grown by 133%.
Reported Earnings • Nov 18First half 2026 earnings released: ₹0.018 loss per share (vs ₹0.002 profit in 1H 2025)First half 2026 results: ₹0.018 loss per share (down from ₹0.002 profit in 1H 2025). Net loss: ₹869.0k (down ₹947.0k from profit in 1H 2025). Over the last 3 years on average, earnings per share has increased by 133% per year but the company’s share price has only increased by 70% per year, which means it is significantly lagging earnings growth.
お知らせ • Nov 03Kashyap Tele-Medicines Limited to Report First Half, 2026 Results on Nov 12, 2025Kashyap Tele-Medicines Limited announced that they will report first half, 2026 results on Nov 12, 2025
お知らせ • Sep 26+ 1 more updateKashyap Tele-Medicines Limited Appoints Kalpesh Bipin Sheth as Managing Director, Effective May 23, 2025Kashyap Tele-Medicines Limited at its AGM held on September 24, 2025 announced the appointment of Mr. Kalpesh Bipin Sheth (DIN: 00405151) as Managing Director of the Company, effective 23rd May, 2025 for the period of five consecutive years.
お知らせ • Aug 25Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025Kashyap Tele-Medicines Limited, Annual General Meeting, Sep 24, 2025, at 11:30 Indian Standard Time.
Reported Earnings • Aug 15First quarter 2026 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in 1Q 2025)First quarter 2026 results: ₹0.006 loss per share (down from ₹0.001 profit in 1Q 2025). Net loss: ₹298.0k (down ₹332.0k from profit in 1Q 2025).
お知らせ • Aug 09Kashyap Tele-Medicines Limited to Report Q1, 2026 Results on Aug 14, 2025Kashyap Tele-Medicines Limited announced that they will report Q1, 2026 results on Aug 14, 2025
Board Change • Aug 01High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Non-Executive & Independent Director Hiren Mehta was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • May 24New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₹860k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹860k free cash flow). Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹432.8m market cap, or US$5.08m).
お知らせ • May 15Kashyap Tele-Medicines Limited to Report Q4, 2025 Results on May 23, 2025Kashyap Tele-Medicines Limited announced that they will report Q4, 2025 results on May 23, 2025
お知らせ • Apr 07Kashyap Tele-Medicines Limited Announces Resignation of Ms. Jyoti Sahu as Whole Time Company Secretary, Compliance Officer, Effective April 6, 2025Kashyap Tele-Medicines Limited announced resignation of Ms. Jyoti Sahu (ICSI A72072) from the position of Whole Time Company Secretary, Compliance Officer and Key Managerial Personnel and she shall not be associated with the Company with effect from 6th April, 2025 to explore further professional growth opportunities. Further there are no other material reasons for resignation other than the one mentioned in her resignation letter dated 5th April, 2025.
Reported Earnings • Feb 13Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: ₹0. Revenue: ₹390.0k (down 14% from 3Q 2024). Net loss: ₹22.0k (down 375% from profit in 3Q 2024).
お知らせ • Feb 05Kashyap Tele-Medicines Limited to Report Q3, 2025 Results on Feb 12, 2025Kashyap Tele-Medicines Limited announced that they will report Q3, 2025 results on Feb 12, 2025
Reported Earnings • Nov 14Second quarter 2025 earnings releasedSecond quarter 2025 results: EPS: ₹0.001. Revenue: ₹550.0k (down 9.8% from 2Q 2024). Net income: ₹44.0k (up ₹42.0k from 2Q 2024). Profit margin: 8.0% (up from 0.3% in 2Q 2024). The increase in margin was driven by lower expenses.
New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹110.2m market cap, or US$1.31m).
お知らせ • Nov 06Kashyap Tele-Medicines Limited to Report Q2, 2025 Results on Nov 11, 2024Kashyap Tele-Medicines Limited announced that they will report Q2, 2025 results on Nov 11, 2024
お知らせ • Aug 28Kashyap Tele-Medicines Limited Announces Cessation of Surabhi Agrawal from the Post of Non-Executive Independent DirectorKashyap Tele-Medicines Limited announced that the Board of Directors in its meeting held on 28 August, 2024, has inter-alia considered and taken note of the cessation of Mrs. Surabhi Agrawal from the post of Non-Executive Independent Director of the Company effective from 22 August, 2024 upon completion of second term of five consecutive years on 21 August, 2024.
お知らせ • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2025 Results on Aug 05, 2024Kashyap Tele-Medicines Limited announced that they will report Q1, 2025 results on Aug 05, 2024
Reported Earnings • Jul 26Full year 2024 earnings released: ₹0.006 loss per share (vs ₹0.001 profit in FY 2023)Full year 2024 results: ₹0.006 loss per share (down from ₹0.001 profit in FY 2023). Revenue: ₹1.92m (down 2.3% from FY 2023). Net loss: ₹300.0k (down ₹331.0k from profit in FY 2023).
お知らせ • Jul 22Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 12, 2024, at 15:00 Indian Standard Time.
お知らせ • Jul 18Kashyap Tele-Medicines Limited Announces Change in Category of Directorship of Amrita Khetan from Non-Executive Non-Independent Director to Non-Executive Independent DirectorKashyap Tele-Medicines Limited at its board meeting held on July 18, 2024 approved change in category of directorship of Mrs. Amrita Khetan (DIN: 02781781) from existing category of "Non-Executive Non-Independent Director" to "Non-Executive Independent Director" of the Company for the first term of 5 consecutive years w.e.f. 19th July, 2024 to 18th July, 2029. Mrs. Amrita Khetan has completed Master of Arts in Sociology from Techno Global University and Bachelor of Arts from Kanpur Vishwavidyalaya. She has approx. 12 years of rich experience in mentorship in Programme Management. She is working as a Team Lead & Pedagogical mentor in Redbricks Education Foundation and also experienced and expertised in strategic thinking and Business management.
New Risk • May 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹112.1m market cap, or US$1.34m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
お知らせ • May 12Kashyap Tele-Medicines Limited to Report Q4, 2024 Results on May 17, 2024Kashyap Tele-Medicines Limited announced that they will report Q4, 2024 results on May 17, 2024
お知らせ • Feb 28Kashyap Tele-Medicines Limited Appoints Jyoti Sahu as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited at its board meeting held on February 27, 2024, has appointed Ms. Jyoti Sahu (ACS-72072), Member of the Institute of Companies Secretaries of India as Company Secretary and Compliance Officer of the Company with effect from February 27, 2024.
New Risk • Feb 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Earnings have declined by 49% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹119.3m market cap, or US$1.44m).
Reported Earnings • Feb 11Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ₹455.0k (down 16% from 3Q 2023). Net income: ₹8.0k (up 33% from 3Q 2023). Profit margin: 1.8% (up from 1.1% in 3Q 2023). The increase in margin was driven by lower expenses.
お知らせ • Feb 01Kashyap Tele-Medicines Limited to Report Q3, 2024 Results on Feb 09, 2024Kashyap Tele-Medicines Limited announced that they will report Q3, 2024 results on Feb 09, 2024
お知らせ • Dec 28Kashyap Tele-Medicines Limited Announces Resignation of Mr. Paritosh Trivedi as Company Secretary and Compliance OfficerKashyap Tele-Medicines Limited informed that the Board of Directors at their meeting held on 27 December, 2023, considered and approved, resignation of Mr. Paritosh Trivedi, Company Secretary & Compliance Officer of the Company. Accordingly, he shall be relieved from his current responsibilities with effect from closing hours of 27th December, 2023. Reason for change: Resignation due to some personal an unavoidable reasons.
お知らせ • Oct 26Kashyap Tele-Medicines Limited to Report Q2, 2024 Results on Nov 06, 2023Kashyap Tele-Medicines Limited announced that they will report Q2, 2024 results on Nov 06, 2023
New Risk • Aug 04New major risk - Revenue and earnings growthEarnings have declined by 70% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 70% per year over the past 5 years. Revenue is less than US$1m (₹1.9m revenue, or US$23k). Market cap is less than US$10m (₹92.6m market cap, or US$1.12m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
お知らせ • Jul 30Kashyap Tele-Medicines Limited to Report Q1, 2024 Results on Aug 03, 2023Kashyap Tele-Medicines Limited announced that they will report Q1, 2024 results on Aug 03, 2023
Reported Earnings • Jul 15Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).
お知らせ • Jul 13Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023Kashyap Tele-Medicines Limited, Annual General Meeting, Aug 03, 2023, at 12:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the Financial Year ended March 31, 2023 together with the Report of the Board of Directors and Report of the Statutory Auditors thereon; to appoint a Director in place of Ms. Amrita Khetan who retires by rotation and being eligible, offers herself for re-appointment; to consider and approve appointment of M/s. Ravi Karia & Associates, Chartered Accountants, Ahmedabad, as Statutory Auditors of the Company and to fix their remuneration; and to consider other matters if any.
New Risk • Jun 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Revenue is less than US$1m (₹2.0m revenue, or US$24k). Market cap is less than US$10m (₹94.5m market cap, or US$1.15m).
Reported Earnings • Jun 03Full year 2023 earnings released: EPS: ₹0.001 (vs ₹0.36 loss in FY 2022)Full year 2023 results: EPS: ₹0.001 (up from ₹0.36 loss in FY 2022). Revenue: ₹1.97m (flat on FY 2022). Net income: ₹31.0k (up ₹17.3m from FY 2022). Profit margin: 1.6% (up from net loss in FY 2022).
お知らせ • May 23Kashyap Tele-Medicines Limited to Report Q4, 2023 Results on May 29, 2023Kashyap Tele-Medicines Limited announced that they will report Q4, 2023 results on May 29, 2023
Board Change • Mar 13Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 14Third quarter 2023 earnings released: EPS: ₹0 (vs ₹0.002 in 3Q 2022)Third quarter 2023 results: EPS: ₹0 (down from ₹0.002 in 3Q 2022). Revenue: ₹542.0k (down 6.6% from 3Q 2022). Net income: ₹6.0k (down 94% from 3Q 2022). Profit margin: 1.1% (down from 17% in 3Q 2022).
お知らせ • Feb 03Kashyap Tele-Medicines Limited to Report Q3, 2023 Results on Feb 10, 2023Kashyap Tele-Medicines Limited announced that they will report Q3, 2023 results on Feb 10, 2023
Board Change • Nov 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 11Second quarter 2023 earnings released: EPS: ₹0 (vs ₹0.001 in 2Q 2022)Second quarter 2023 results: EPS: ₹0 (down from ₹0.001 in 2Q 2022). Revenue: ₹510.0k (up 7.4% from 2Q 2022). Net income: ₹13.0k (down 71% from 2Q 2022). Profit margin: 2.5% (down from 9.3% in 2Q 2022).
お知らせ • Nov 03Kashyap Tele-Medicines Limited to Report Q2, 2023 Results on Nov 09, 2022Kashyap Tele-Medicines Limited announced that they will report Q2, 2023 results on Nov 09, 2022
Board Change • Aug 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. CFO & Non-lndependent Director Raghav Agrawal was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.